Pricing, deals and trends across European healthcare.
- Sector article
ESMO 2026: big pharma and China raised the bar for European oncology biotech — 29 October 2026
None of the 12 Presidential late-breakers at ESMO 2026 came from a European biotech; Genmab matched big pharma with two Phase 3 survival wins in the same week, while the other Research-list companies brought early data against a higher bar.
Read the article →